I

Ivanesemab

Product

by Summit Therapeutics

Heard in 4 episodes across 3 shows since Sep 2026

Ivanesemab appears to be an investigational therapeutic antibody candidate. Available search evidence indicates it was designed with an extended half-life and evaluated in the context of oncology drug development, but reliable public information about its precise target, indication, development status, and formulation is limited.

Episodes

4
across 3 shows

First heard

Sep 2026

Expert statements

1
1 negative

Episodes per month

Public PodLume episodes featuring it, over the last year.

Show the data
MonthEpisodes
Dec 20250
Jan 20260
Feb 20260
Mar 20260
Apr 20260
May 20260
Jun 20260
Jul 20260
Aug 20260
Sep 20261
Oct 20261
Nov 20262

Email alert

Email me when Ivanesemab comes up on a podcast

One email a week at most, with the new episodes that mention Ivanesemab. Free, no account needed, unsubscribe in one click.

What experts have said about Ivanesemab

1 statement · 1 negative

  1. Adam FeuersteinNegativeNov 20, 2026· The Readout Loud

    The FDA rejected Summit’s ibanesimab application after warning that survival benefit was needed.

    “the FDA told Summit that without a survival benefit, you shouldn't file this drug for approval. Summit did that anyway, didn't listen to the FDA, filed the drug, and lo and behold, we found out over the weekend that the FDA rejected it.”

    Listen at 10:35

    Open the episode · 422: FDA's search for a new leader, and China's largest drugmakers

Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.

Episodes

4 episodes featuring Ivanesemab, newest first